P46 SEER-MEDICARE DATABASE: REAL-WORLD TREATMENTS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED MULTIPLE MYELOMA TREATED WITH 1–3 PRIOR LINES OF THERAPY, INCLUDING A PI AND IMID

P46 SEER-MEDICARE DATABASE: REAL-WORLD TREATMENTS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED MULTIPLE MYELOMA TREATED WITH 1–3 PRIOR LINES OF THERAPY, INCLUDING A PI AND IMID

Bibliographic Details
Main Authors:	H. Einsele, B. Dhakal, R. Potluri, J. Schecter, W. Deraedt, N. Lendvai, A. Slaughter, C. Lonardi, S. Nair, J. He, J. Voelker, P. Cost, S. Valluri, F. Yalniz, L. Pacaud, K. Yong
Format:	Article
Language:	English
Published:	Wiley 2023-05-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000936312.94801.44

Similar Items

P899: REAL-WORLD ASSESSMENT OF TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE OPTUM DATABASE
by: B. Dhakal, et al.
Published: (2022-06-01)

P35 ANALYSIS OF DARATUMUMAB CLINICAL TRIALS: CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH 1-3 PRIOR LINES OF THERAPY
by: H. Einsele, et al.
Published: (2023-05-01)

S100: FIRST PHASE 3 RESULTS FROM CARTITUDE-4: CILTA-CEL VERSUS STANDARD OF CARE (PVD OR DPD) IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA
by: Hermann Einsele, et al.
Published: (2023-08-01)

IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?
by: Kazuhito Suzuki, et al.
Published: (2023-11-01)

Hepatocellular Carcinoma Survival by Etiology: A SEER‐Medicare Database Analysis
by: Gagandeep Brar, et al.
Published: (2020-10-01)

Examining the relationship between metformin dose and cancer survival: A SEER-Medicare analysis
by: Lisa Scarton, et al.
Published: (2022-01-01)

Examining the relationship between metformin dose and cancer survival: A SEER-Medicare analysis.
by: Lisa Scarton, et al.
Published: (2022-01-01)

Racial Disparities in Breast Cancer Treatments and Adverse Events in the SEER-Medicare Data
by: Robert Wieder, et al.
Published: (2023-08-01)

Using Pointwise Mutual Information for Breast Cancer Health Disparities Research With SEER-Medicare Claims
by: Brian L. Egleston, et al.
Published: (2023-03-01)

Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma
by: C. Cerchione, et al.
Published: (2020-10-01)

P959: CILTACABTAGENE AUTOLEUCEL IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY: CARTITUDE-2 BIOLOGICAL CORRELATIVE ANALYSES AND UPDATED CLINICAL DATA
by: J. Hillengass, et al.
Published: (2022-06-01)

IMID-Biobank: Biobank of immune-mediated inflammatory diseases (IMIDs)
by: Julià A, et al.
Published: (2010-11-01)

Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front‐line regimens using the SEER‐Medicare data
by: Daisuke Goto, et al.
Published: (2020-01-01)

The association of statin use after cancer diagnosis with survival in pancreatic cancer patients: a SEER-medicare analysis.
by: Christie Y Jeon, et al.
Published: (2015-01-01)

Epidemiology and outcomes of previously undiagnosed diabetes in older women with breast cancer: an observational cohort study based on SEER-Medicare.
by: Griffiths, R, et al.
Published: (2012)

P08: CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY
by: H Einsele, et al.
Published: (2022-04-01)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
by: van de Donk NW, et al.
Published: (2012-08-01)

Treatment Patterns and Survival in Locally Advanced or Metastatic Biliary Tract Cancer Using SEER Medicare Data
by: Mark D. Danese, et al.
Published: (2023-01-01)

Risk factors for venous thromboembolism in metastatic colorectal cancer with contemporary treatment: A SEER‐Medicare analysis
by: Steven Ades, et al.
Published: (2022-04-01)

Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: A population-based study in SEER-Medicare.
by: Jessica L Petrick, et al.
Published: (2017-01-01)

Disparities in cancer-specific and overall survival in black women with endometrial cancer: A Medicare-SEER study
by: Daniel H. Saris, et al.
Published: (2022-04-01)

Treatment patterns and burden of myelosuppression for patients with small cell lung cancer: A SEER‐medicare study
by: Robert S. Epstein, et al.
Published: (2022-01-01)

Correction: The Association of Statin Use after Cancer Diagnosis with Survival in Pancreatic Cancer Patients: A SEER-Medicare Analysis.
by: Christie Y Jeon, et al.
Published: (2015-01-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
by: Cirino Botta, et al.
Published: (2021-04-01)

Identification of Prognostic and Chemopredictive microRNAs for Non-Small-Cell Lung Cancer by Integrating SEER-Medicare Data
by: Qing Ye, et al.
Published: (2021-07-01)

Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: A SEER‐Medicare investigation
by: Jennifer L. Beebe‐Dimmer, et al.
Published: (2019-06-01)

Immunomodulatory Compounds (Imids®) in the Treatment of Multiple Myeloma
by: Gordan Srkalovic, et al.
Published: (2009-10-01)

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
by: Carlyn Rose Tan, et al.
Published: (2023-07-01)

GWAS in IMIDs
by: Plenge R M
Published: (2010-11-01)

Impact of timing to initiate adjuvant therapy on survival of elderly glioblastoma patients using the SEER-Medicare and national cancer databases
by: Ping Zhu, et al.
Published: (2023-02-01)

Epidemiology and outcomes of previously undiagnosed diabetes in older women with breast cancer: an observational cohort study based on SEER-Medicare
by: Griffiths Robert I, et al.
Published: (2012-12-01)

Survival associated with chronic obstructive pulmonary disease among SEER-Medicare beneficiaries with non-small-cell lung cancer
by: Shah S, et al.
Published: (2019-04-01)

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
by: Zhongjun Huo, et al.
Published: (2023-02-01)

Inverse probability weighted least squares regression in the analysis of time-censored cost data: an evaluation of the approach using SEER-Medicare.
by: Griffiths, R, et al.
Published: (2012)

Cancer-of-Unknown-Primary-Origin: A SEER–Medicare Study of Patterns of Care and Outcomes among Elderly Patients in Clinical Practice
by: Linda Mileshkin, et al.
Published: (2022-06-01)

Associations between initiating antihypertensive regimens on stage I–III colorectal cancer outcomes: A Medicare SEER cohort analysis
by: Rajesh Balkrishnan, et al.
Published: (2021-08-01)

How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
by: Felipe de Arriba de la Fuente, et al.
Published: (2022-12-01)

Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
by: Adrian Alegre, et al.
Published: (2012-01-01)